New progress in treatment of chronic thromboembolic pulmonary hypertension

doi:10.3877/cma.j.issn.1674-0785.2017.20.009

Abstract

Abstract:

Chronic thromboembolic pulmonary hypertension (CTEPH) is a progressive disease with poor prognosis if not treated. Pulmonary endarterectomy is currently the standard of treatment as it is potentially curative. However, 30%-50% of patients is inoperable due to either distal pulmonary vascular obstruction or significant comorbidities. The development of targeted drugs and balloon pulmonary angioplasty has brought a new dawn to these patients. This paper discusses the latest research on the treatment of CTEPH.

Key words: Chronic thromboembolic pulmonary hypertension, Pulmonary endarterectomy, Targeted drugs

Feng Wang, Xiaoyun Hu, Yeqin Zhang. New progress in treatment of chronic thromboembolic pulmonary hypertension[J]. Chinese Journal of Clinicians(Electronic Edition), 2017, 11(20): 2335-2339.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcyszz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0785.2017.20.009

https://zhlcyszz.cma-cmc.com.cn/EN/Y2017/V11/I20/2335

Figures/Tables 1

References 30

[1]	Lang IM, Pesavento R, Bonderman D, et al. Risk factors and basic mechanisms of chronic thromboembolic pulmonary hypertension: a current understanding [J]. Eur Respir J, 2013, 41(2): 462-468.
[2]	Lau EM, Tamura Y, MeGoon MD, et al. The 2015ESC/ERS Guidelines for the diagnosis and reatment of pulmonary hypertension: a practical chronicle of progress [J]. Eur Respir J, 2015, 46(4): 879-882.
[3]	D′Armini AM, Morsolini M, Mattiucci G, et al. Pulmonary endarterectomy for distal chronic thromboembolic pulmonary hypertension [J]. J Thorac Cardiovasc Surg, 2014, 148(3): 1005-1012; e1-2.
[4]	Mazurek A, Dziuk M, Witkowska-Patena E, et al. The utility of hybrid SPECT/CT lung perfusion scintigraphy in pulmonary embolism diagnosis [J]. Respiration, 2015, 90(5): 393-401.
[5]	Callahan J, Hofman MS, Siva S, et al. High-resolution imaging of pulmonary ventilation and perfusion with 68Ga-VQ respiratory gated(4-D) PET/CT [J]. Eur J Nucl Med Mol Imaging, 2014, 41(2): 343-349.
[6]	Nierlich P, Hold A, Ristl R. Outcome after surgical treatment of chronic thromboembolic pulmonary hypertension: dealing with different patient subsets. A single-centre experience [J]. Eur J Cardiothorac Surg, 2016, 50(5): 898-906.
[7]	López Gude MJ, Pérez de la Sota E, Forteza Gil A, et al. Pulmonary Thrombo endarterectomy in 106 Patients With Chronic Thromboembolic Pulmonary Hypertension [J]. Arch Bronconeumol, 2015, 28: 300-304.
[8]	Rolf A, Rixe J, Kim WK, et al. Pulmonary vascular remodeling before and after pulmonary endarterectomy in patients with chronic thromboembolic pulmonary hypertension: a cardiac magnetic resonance study [J]. Int J Cardiovasc Imaging, 2015, 31: 613-619.
[9]	Ben-Dov I, Kogan A, Preisman S, et al. Chronic thromboembolic pulmonary hypertension: can successful thrombendarterectomy normalize exercise capacity and gas exchange? [J]. Harefuah, 2012, 151(2): 74-78, 128-129.
[10]	Nagel C, Prange F, Guth S, et al. Exercise training improves exercise capacity and quality of life in patients with inoperable or residual chronic thromboembolic pulmonary hypertension [J]. PLoS One, 2012, 7(7): e41603.
[11]	Ghofrani HA, D'Armini AM, Grimminger F, et al. CHEST-1 study group. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension [J]. N Engl J Med, 2013, 369: 319-329.
[12]	Simonneau G, D′Armini AM, Ghofrani HA, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2) [J]. Eur Respir J, 2015, 45: 1293-1302.
[13]	Ghofrani HA, Grimminger F, Grünig E, et al. Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial [J]. Lancet Respir Med, 2016, 4(5): 361-371.
[14]	Jaïs X, D′Armini AM, Jansa P, et al. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT(Bosentan effects in iNopErable forms of chronic thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial [J]. J Am Coll Cardiol, 2008, 52(25): 2127-2134.
[15]	Nishikawa-Takahashi M, Ueno S, Kario K. Long-term advanced therapy with bosentan improves symptoms and prevents deterioration of inoperable chronic thromboembolic pulmonary hypertension [J]. Life Sci, 2014, 118(2): 410-413.
[16]	Abe S, Ishida K, Masuda M, et al. A prospective, randomized study of inhaled prostacyclin versus nitric oxide in patients with residual pulmonary hypertension after pulmonary endarterectomy [J]. Gen Thorac Cardiovasc Surg, 2017, 65(3):153-159.
[17]	Suntharalingam J, Treacy CM, Doughty NJ, et al. Long-term use of sildenafil in inoperable chronic thromboembolic pulmonary hypertension [J]. Chest, 2008, 134: 229-236.
[18]	Reesink HJ, Surie S, Kloek JJ, et al. Bosentan as a bridge to pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension [J]. J Thorac Cardiovasc Surg, 2010, 139: 85-91.
[19]	Surie S, Reesink HJ, Marcus JT, et al. Bosentan treatment is associated with improvement of right ventricular function and remodeling in chronic thromboembolic pulmonary hypertension. Clin Cardiol, 2013, 36: 698-703.
[20]	Pepke-Zaba J, Delcroix M, Lang I, et al. Chronic thromboembolic pulmonary hypertension(CTEPH): results from an international prospective registry [J]. Circulation, 2011, 124: 1973-1981.
[21]	Ishiguro H, Kataoka M, Inami T, et al. Percutaneous transluminal pulmonary angioplasty for central-type chronic thromboembolic pulmonary hypertension [J]. JACC Cardiovasc Interv, 2013, 6(11): 1212-1213.
[22]	Kawakami T, Ogawa A, Miyaji K, et al. Novel angiographic classification of each vascular lesion in chronic thromboembolic pulmonary hypertension based on selective angiogram and results of balloon pulmonary angioplasty [J]. Circ Cardiovasc Interv, 2016, 9(10): e003318.
[23]	Fukui S, Ogo T, Morita Y, et al. Right ventricular reverse remodelling after balloon pulmonary angioplasty [J]. Eur Respir J, 2014, 43: 1394-1402.
[24]	Taniguchi Y, Miyagawa K, Nakayama K, et al. Balloon pulmonary angioplasty: an additional treatment option to improve the prognosis of patients with chronic thromboembolic pulmonary hypertension [J]. Euro Intervention, 2014, 10(4): 518-525.
[25]	Andreassen AK, Ragnarsson A, Gude E, et al. Balloon pulmonary angioplasty in patients with inoperable chronic thromboembolic pulmonary hypertension [J]. Heart, 2013, 99(19): 1415-1420.
[26]	Tatebe S, Sugimura K, Aoki T, et al. Multiple beneficial effects of balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension [J]. Circ J, 2016, 80(4): 980-988.
[27]	Inami T, Kataoka M, Shimura N, et al. Pressure-wire-guided percutaneous transluminal pulmonary angioplasty: a breakthrough in catheterinterventional therapy for chronic thromboembolic pulmonary hypertension [J]. JACC Cardiovasc Interv, 2014, 7: 1297-1306.
[28]	Inagaki T, Terada J, Tanabe N, et al. Home-based pulmonary rehabilitation in patients with inoperable or residual chronic thromboembolic pulmonary hypertension: a preliminary study [J]. Respir Investig, 2014, 52: 357-364.
[29]	Ivarsson B, Ekmehag B, Hesselstrand R. et al. Perceptions of received information, social support, and coping in patients with pulmonary arterial hypertensionor chronic thromboembolic pulmonary hypertension [J]. Clin Med Insights Circ Respir Pulm Med, 2014, 8: 21-28.
[30]	王平生，刘晓静，孙尚帛, 等. 中西医结合治疗慢性肺血栓栓塞性肺动脉高压30例临床研究 [J]. 江苏中医药, 2016, 48(6): 28-30.

Please choose a citation manager

Content to export